Outcome

The study provides promising evidence that hyperbaric oxygen therapy (HBOT) significantly improves insulin sensitivity in type 2 diabetes patients with acute intracerebral hemorrhage. The results demonstrated significant increases in glucose infusion rates and notable reductions in serum insulin fasting glucose and hemoglobin A1C following HBOT.

Introduction

Hyperbaric oxygen therapy (HBOT) significantly improves insulin sensitivity in type 2 diabetes patients with acute intracerebral hemorrhage. The study found increased glucose infusion rates and reduced serum insulin fasting glucose and hemoglobin A1C after HBOT. Both early and late clinical outcomes improved compared to baseline supporting HBOT’s efficacy and safety as an adjunctive treatment for diabetes patients with acute stroke.

Results

The study investigated the effects of hyperbaric oxygen therapy (HBOT) on peripheral insulin sensitivity in type 2 diabetes patients with acute intracerebral hemorrhage. The primary findings demonstrated that HBOT significantly enhanced insulin sensitivity evidenced by a noteworthy 37.8% ± 5.76% increase in glucose infusion rate after one month compared to baseline values.

In addition to improved glucose infusion rates there were significant reductions in several key metabolic parameters. Serum insulin levels decreased and both fasting glucose and hemoglobin A1C levels were notably reduced following the HBOT treatment.

Clinical outcomes were also positively impacted by HBOT. Early and late outcomes measured using the National Institutes of Health Stroke Scale (NIHSS) displayed significant improvement. Scores were significantly better in the HBOT group at both 10 days and one month after onset compared to baseline. The statistical analysis revealed a significant difference between the HBOT group and the control group in terms of changes in NIHSS scores underscoring the comparative effectiveness of HBOT.

These findings provide compelling evidence that HBOT not only enhances peripheral insulin sensitivity but also contributes to better overall clinical outcomes for type 2 diabetes patients experiencing acute intracerebral hemorrhage. The results suggest that HBOT is a potentially effective and safe adjunctive treatment for managing acute stroke in diabetic patients contributing to improved metabolic control and stroke recovery.

Conclusion

In conclusion this study provides compelling evidence that hyperbaric oxygen therapy (HBOT) significantly enhances insulin sensitivity in type 2 diabetes patients suffering from acute intracerebral hemorrhage. Key findings include notable increases in glucose infusion rates and reductions in serum insulin fasting glucose and hemoglobin A1C levels following HBOT. Furthermore both early and late clinical outcomes as measured by the National Institutes of Health Stroke Scale (NIHSS) showed marked improvement underlining HBOT’s potential efficacy and safety as a supportive treatment.

These results indicate that HBOT not only aids in better glucose management but also contributes to improved stroke recovery in this patient population. The observed benefits highlight the promise of HBOT as an adjunctive therapy pointing to its potential to address some of the complex challenges faced by diabetes patients experiencing acute strokes.

Given these promising outcomes further research is warranted to explore the long-term effects of HBOT and better understand the underlying mechanisms. Future studies could also investigate the optimal HBOT protocols to maximize therapeutic benefits thereby reinforcing its role in the integrated management of diabetes and stroke.